Eli Lilly says its experimental Alzheimer’s drug appears to slow symptoms
[ad_1] Eli Lilly said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study, sending its stock up by 5% on investor optimism about the results. In the 18-month trial, people in the early stages of Alzheimer’s who received infusions of donanemab showed 35% less decline in thinking…